Rigel Pharmaceuticals (RIGL) gains 1.19% for July 21

Equities Staff  |

Rigel Pharmaceuticals (NASDAQ: RIGL) shares gained 1.19%, or $0.05 per share, to close Wednesday at $4.25. After opening the day at $4.21, shares of Rigel fluctuated between $4.27 and $4.13. 607,453 shares traded hands a decrease from their 30 day average of 1,332,635. Wednesday's activity brought Rigel’s market cap to $723,198,415.

Rigel is headquartered in South San Francisco, California..

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.

Visit Rigel Pharmaceuticals’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Rigel Pharmaceuticals and to follow the company’s latest updates, you can visit the company’s profile page here: Rigel Pharmaceuticals’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content